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BACKGROUND:Uterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immuno-
conjugate molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human Factor VII
(fVII) as the targeting domain, fused to human immunoglobulin (Ig) G1 Fc as an effector domain. We evaluated hI-con1 potential
activity against primary chemotherapy-resistant USPC cell lines expressing different levels of TF.
METHODS: A total of 16 formalin-fixed, paraffin-embedded USPC samples were evaluated by immunohistochemistry (IHC) for
TF expression. Six primary USPC cell lines, half of which overexpress the epidermal growth factor type II (HER2/neu) receptor at
3þ levels, were assessed by flow cytometry and real-time PCR for TF expression. Sensitivity to hI-con1-dependent cell-mediated
cytotoxicity (IDCC) was evaluated in 5-hour-chromium release assays. Finally, to investigate the effect of interleukin-2 (IL-2) on
IDCC, 5-h
51Cr assays were also conducted in the presence of low doses of IL-2 (i.e., 50–100IUml
 1).
RESULTS:Cytoplasmic and/or membrane TF expression was observed in all 16 (100%) USPC samples tested by IHC, but not in normal
endometrium. High expression of TF was found in 50% (three out of six) of the USPC cell lines tested by real-time PCR and flow
cytometry when compared with normal endometrial cells (NECs; Po0.001). Uterine serous papillary adenocarcinoma cell lines
overexpressing TF, regardless of their high or low HER2/neu expression, were highly sensitive to IDCC (mean killing±s.d.,
65.6±3.7%, range 57.5–77.0%, Po0.001), although negligible cytotoxicity against USPC was seen in the absence of hI-con1 or in the
presence of Rituximab control antibody. The addition of low doses of IL-2 further increased the cytotoxic effect induced by hI-con1
against chemotherapy-resistant USPC.
CONCLUSION: hI-con1 induces strong cytotoxicity against primary chemotherapy-resistant USPC cell lines overexpressing TF. The
hI-con1 may represent a novel therapeutic agent for the treatment of patients harbouring advanced, recurrent and/or metastatic
USPC refractory to standard treatment modalities.
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Endometrial cancer is the most common female genital tract
malignancy in the United States, with an incidence of 40100 new
cases and 7470 deaths in the United States in 2009 (Jemal et al,
2009). Two subtypes of endometrial carcinoma, namely type I and
type II tumours, have been described on the basis of both clinical
and histopathological variables (Bohkman, 1983). Type I endo-
metrial cancers, which account for the majority of cases, are
usually well differentiated and endometrioid in histology. These
neoplasms are frequently diagnosed in younger women, are
associated with a history of hyperestrogenism as the main risk
factor, and typically have a favourable prognosis with appropriate
therapy. In contrast, type II endometrial cancers include poorly
differentiated endometrioid tumours (G3-endometrial endome-
trioid carcinoma), serous papillary (uterine serous papillary
adenocarcinoma (USPC)) and clear cells endometrial carcinomas
(Bohkman, 1983). Although these tumours account for a minority
of endometrial cancers the striking majority of relapses and deaths
occur in this group of patients (Hendrickson et al, 1982; Goff et al,
1994; Chan et al, 2003; Schwartz, 2006). The development of novel
therapeutic strategies against this aggressive subset of endometrial
cancers remains a high priority.
Uterine serous tumours, which accounts for about 10% of
endometrial cancers, have a higher propensity for lymphovascular
invasion, and intraperitoneal as well as extra-abdominal spread,
than endometrioid carcinoma. At the time of presentation,
approximately 60–70% of women with USPC will have disease
spread outside the uterus (Hendrickson et al, 1982). Unlike the
histologically similar high-grade ovarian cancer, USPC is a chemo-
resistant disease from onset, with in vivo responses to combined
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scisplatin-based chemotherapy in the order of 20% and of short
duration (Hendrickson et al, 1982; Levenback et al, 1992;
Chan et al, 2003). Our group has recently reported HER2/neu
overexpression by immunohistochemistry (IHC) and also ampli-
fication of the c-erbB2 gene by fluorescence in situ hybridi-
sation in a large percentage of patients harbouring USPC
(Santin et al, 2002, 2005a,b,c). These findings, recently confirmed
by other groups (Diaz-Montes et al, 2006) including
the Gynaecologic Oncology Group in a cooperative multicentric
study (Grushko et al, 2008), have identified HER2/neu over-
expression in USPC, as an independent variable associated with
poor outcome and as the one that occurs more frequently in
African–American women than in Caucasian women (Santin et al,
2002, 2005c).
Pathological angiogenesis, the formation of new capillary blood
vessels from existing blood vessels into diseased tissues, has been
previously reported to occur more frequently in endometrial carci-
nomas developing against a background of endometrial atrophy
rather than carcinomas arising from a hyperplastic endometrium
(Abulafia et al, 1999). Tissue factor, a transmembrane receptor for
coagulation factor VII/VIIa, is aberrantly expressed in human
cancers and on endothelial cells within the tumour vasculature
(Contrino et al, 1996; Papetti and Herman, 2002). Importantly,
tumour cells characterized by a high production of TF and vascular
endothelial growth factor, a crucial initiator of angiogenesis, are
known to generate solid tumours characterized by intense
vascularity and highly aggressive behaviour (Abe et al, 1999).
Consistent with this view, vascular endothelial growth factor
expression at the invading tumour front is reported to be 4–10
times higher than in the inner tumour areas and is significantly
associated with poor prognosis, particularly within stage I
endometrial cancer (Abulafia et al, 1999; Bristow, 1999). Although
a direct regulation of vascular endothelial growth factor expression
in human tumour cells by the cytoplasmic tail of TF has been
previously shown (Abe et al, 1999), recent studies indicate that
type-2 proteinase activated receptor is intimately involved in
TF-mediated signalling and angiogenesis (Ruf, 2007). These
data suggest a potential direct role for TF in tumour growth
(Ruf, 2007).
The hI-con1 is a previously characterized immunoconjugate
molecule developed against TF (Hu et al, 1999; Hu and Garen,
2000, 2001). It is composed of two identical protein chains
consisting of human Factor VII (fVII) as the targeting domain
fused to human immunoglobulin (Ig) G1 Fc as the effector domain;
the two chains are held together by the disulphide bonds normally
present in IgG. The hI-con1 is designed to bind to TF with far
higher affinity and specificity than that can be achieved with an
anti-TF antibody. Indeed, the hI-con1 has several important
advantages over monoclonal antibodies for targeting TF, includ-
ing: (1) the Kd for fVII binding to TF is about 10
 12 M (Waxman
et al, 1992), in contrast to anti-TF antibodies that have a Kd in
the range of 10
 8–10
 9 M for TF (Presta et al, 2001) and (2) the
hI-con1 is produced by recombinant DNA technology, allowing
a completely human hI-con1 to be made for future clinical
trials. Because binding of the fVII to TF could induce dissemi-
nated intravascular coagulation, a potentially lethal vascular
disease, an amino-acid substitution was introduced into the
fVII domain of the hI-con1 (Lysine 341 to Alanine) to inhibit
initiation of the coagulation pathway without reducing the
strong affinity for TF (Hu et al, 1999; Dickinson et al, 2006).
The human Fc domain of the hI-con1 may thus potentially
activate powerful cytolytic responses mediated by antibody-
dependent cell-mediated cytotoxicity against both TF-expressing
tumour cells and tumour vascular endothelial cells that bind
the hI-con1 molecule. In this study, we evaluated for the first
time the in vitro potential of hI-con1 as a novel immuno-
therapeutic agent against biologically aggressive uterine serous
tumours.
METHODS
Tissue factor immunostaining of formalin-fixed
USPC tissues
Formalin-fixed, paraffin-embedded tissue blocks from 16 patients
harbouring stage I (6 patients), stage II (2 patients), stage III
(6 patients) and stage IV (2 patients) USPC were retrieved from
the surgical pathology files at Yale University. Specimens were
reviewed by a surgical pathologist (NB). The level of TF expression
was then evaluated on the most representative block by standard
immunohistochemical staining. For IHC, 4mm sections were cut
from the formalin-fixed paraffin-embedded blocks. After depar-
affinization and rehydration, endogenous peroxidase was blocked
in 3% H2O2. Steam and high pH (pH 9) were used for antigen
retrieval. The slides were then incubated overnight at 41C with
monoclonal anti-TF antibody (no. 4509, 1:10 dilution; American
Diagnostica, Stamford, CT, USA). EnVisionTM system (Dako,
Carpinteria, CA, USA) was used for secondary detection and the
reactions were visualised with diaminobenzidine. Appropriate
positive and negative controls were used with each case. Both
cytoplasmic and membranous immunoreactivity were considered
positive. Immunostaining was assessed using a semi-quantitative
scoring system, as follows: 0, negative (0–5% staining); 1þ,
weakly positive (10–20%); 2þ, moderately positive (20–50%);
3þ and 4þ, strongly positive (50–75% and 475%, respectively),
as previously described (Kaushal et al, 2008).
Establishment of USPC cell lines
Primary USPC tumour cell lines from six patients with invasive
USPC were obtained from fresh tumour biopsies collected at the
time of surgery, under the approval of the Institutional Review
Board. Tumours were staged according to the International
Federation of Gynaecologists and Obstetricians operative staging
system. Six primary USPC cell lines (USPC-ARK-1, USPC-ARK-2,
USPC-ARK-3, USPC-ARK-4, USPC-ARK-5 and USPC-ARK-6) were
established after sterile processing of the tumour samples from
surgical biopsies as described previously (Cross et al, 2010).
Source–patient characteristics of these six USPC cell lines are
described in Table 1. The amplification of the c-erbB2 gene by
fluorescence in situ hybridisation, expression levels of HER2/neu
receptor by IHC and mRNA expression levels by quantitative real-
time PCR (qRT–PCR) for these primary USPC cell lines have been
recently reported (El-Sahwi et al, 2010).
Quantitative real-time PCR
RNA isolation from all the six primary USPC cell lines used in the
cytotoxicity experiments were performed using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Quantitative PCR was performed using a 7500 Real-time
Table 1 Patient characteristics, from which the six USPC cell lines
were established
Patient
Age
(years) Race
Year of
diagnosis
FIGO
stage
USPC
histopathology
USPC-ARK-1 62 AA 1997 IVA Pure
USPC-ARK-2 63 AA 1998 IVB Pure
USPC-ARK-3 59 AA 2006 IVB Mixed
USPC-ARK-4 73 C 2004 IVB Pure
USPC-ARK-5 73 AA 2006 IIIC Pure
USPC-ARK-6 62 C 2005 IB Mixed
Abbreviations: AA¼African American; C¼Caucasian; FIGO¼International
Federation of Gynaecologist and Obstetrics; USPC¼uterine serous papillary
adenocarcinoma.
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sPCR System with the manufacturer’s recommended protocol
(Applied Biosystems, Foster City, CA, USA) to evaluate expression
of TF in all samples. Each reaction was run in duplicate. Briefly,
5mg of total RNA from each sample was reverse transcribed using
SuperScript III first-strand cDNA synthesis (Invitrogen). A total of
5ml of reverse transcribed RNA samples (from 500mlo ft o t a lv o l u m e )
was amplified using the TaqMan Universal PCR Master Mix (Applied
Biosystems) to produce PCR products specific for TF. The primers
and probe for TF were obtained from Applied Biosystems (assay ID
Hs01076032_m1). The comparative threshold cycle (CT)m e t h o d
(Applied Biosystems) was used to determine gene expression in each
sample relative to the value observed in the lowest non-malignant
endometrial epithelial-cell sample, using glyceraldehyde-3-phosphate
dehydrogenase (assay ID Hs99999905_m1) RNA as internal control.
Flow cytometry
Clinical grade hI-con1 was produced for Iconic Therapeutics Inc.
(Atlanta, GA, USA) by Laureate Pharma, (Princeton, NJ, USA) by
cultivation of baby hamster kidney cells transfected with a vector
containing the gene sequence originally described by Hu and Garen
(2000, 2001; Hu et al, 1999). The protein was purified by a series of
chromatographic steps to a purity adequate for clinical use,
formulated in 15mM HEPES, 150mM NaCl, 5mM CaCl2,2 5 m M
arginine and 0.01% Tween 80, pH 7.4 buffer, and was sterile filtered.
It was provided in aliquots of 80ml at a stock concentration of
350mgml
 1, which were used for our flow cytometry and hI-con1-
dependent cell-mediated cytotoxicity (IDCC) studies. Briefly, USPC
cell lines and phytohemagglutinin (PHA)-stimulated control
peripheral blood lymphocytes (PBLs) were stained with hI-con1
at a concentration of 30mgml
 1 for 30min on ice or with a
commercially available fluorescein isothiocyanate-conjugated mouse
anti-human TF Ig (i.e., positive control; BioSource International,
Camarillo, CA, USA). After hI-con1 staining, cells were washed twice
with the same buffer and secondary goat-anti-mouse antibody (IgG1-
FITC (fluorescein isothiocyanate), catalogue no. F0767 Sigma
Aldrich, St Louis, MO, USA) was added for further 30min. Analysis
was conducted with a FACSCalibur instrument using Cell Quest
software (Becton Dickinson, Franklin Lakes, NJ, USA).
Tests for IDCC
A standard 5-h chromium (
51Cr) release assay was performed to
measure the cytotoxic reactivity of Ficoll–Hypaque-separated
PBLs from several healthy donors in combination with hI-con1
against USPC target cell lines. The release of
51Cr from the target
cells was measured, as described (Santin et al, 1999), as evidence
of tumour cell lysis after exposure of tumour cells to various
concentrations of hI-con1 (ranging from 1 to 80mgml
 1) and
different target/effector cell ratios. Controls included the incuba-
tion of target cells alone or with PBLs, or monoclonal antibody
(mAb) separately. The chimeric anti-CD20 mAb Rituximab
(Rituxan; Genentech, San Francisco, CA, USA) was used as control
in all bioassays. The hI-con1-dependent cell-mediated cytotoxicity
was calculated as the percentage of killing of target cells observed
with mAb plus effector cells as compared with
51Cr release from
target cells incubated alone.
Interleukin-2 enhancement of IDCC
To investigate the effect of IL-2 on IDCC, effector PBLs were
incubated for 5h at 371C, with a final concentration of IL-2
(Aldesleukin; Chiron Therapeutics, Emeryville, CA, USA) ranging
from 50 to 100IUml
 1 in 96-well microtiter plates. Target cells
were primary USPC cell lines exposed to hI-con1 (concentrations
ranging from 1 to 80mgml
 1), whereas controls included the
incubation of target cells alone or with PBLs in the presence or
absence of IL-2 or mAb, respectively. Rituximab was used as a
control mAb. The hI-con1-dependent cell-mediated cytotoxicity
was calculated as the percentage of killing of target cells observed
with mAb plus effector PBLs, as compared with target cells
incubated alone. Each experiment was performed with PBLs
collected from multiple normal donors and results from a
representative donor are presented.
Statistical analysis
For qRT–PCR data, the right-skewing was removed by taking
copy-number ratios relative to the lowest expressing normal
endometrial cell (NEC) sample (‘relative copy numbers’), log2
transforming them to DCTs, and comparing the results via unequal
variance t-test for the USPC vs NEC difference. Group means with
95% confidence limits (confidence intervals) were calculated by
computing them on the DCTs and then reverse transforming
the results to obtain means (95% confidence intervals) of relative
copy numbers. Differences in TF expression by flow cytometry
were analysed by the unpaired t-test. Kruskal–Wallis test and
w
2-analysis was used to evaluate differences in hI-con1-induced
cellular cytotoxicity levels in primary tumour cell lines. Statistical
analysis was performed using SPSS version 15 (SPSS, Chicago, IL,
USA). A P-value of o0.05 was considered statistically significant.
RESULTS
Tissue-factor expression by IHC in USPC samples
We performed immunohistochemical analysis of TF protein
expression on formalin-fixed tumour tissues from 16 paraffin-
embedded uterine serous carcinoma specimens. As representa-
tively shown in Figure 1, with no exception, all USPC samples
that were tested showed either membrane and/or cytoplasmic
immunoreactivity for TF (i.e., all 16 samples¼100%), whereas the
non-neoplastic endometrial controls were negative. The staining
intensity was focal (1þ) in nine cases, moderately positive (2þ)
in four cases and strongly positive (3þ) in two cases.
Tissue-factor expression by qRT–PCR in USPC primary
cell lines
A total of six primary USPC lines, half of which overexpress
HER2/neu at 3þ level and show amplification of the C-erbB2 gene
by fluorescence in situ hybridisation, were tested for TF expression
by qRT–PCR. Table 2 shows mRNA levels for TF in all USPC cell
lines relative to the value observed in the lowest non-malignant
endometrial epithelial-cell sample. Of the six tumours tested, three
showed a high mRNA copy number (i.e., USPC-ARK-2, USPC-
ARK-3 and USPC-ARK-6) ranging from 280 to 816 (Table 2).
The TF expression between these USPC cell lines and NECs was
statistically significant at P¼0.01. The fold change in the mean
relative copy numbers between high USPC TF expressers vs NECs
was 8.7 (P¼0.01). In contrast, low TF expression using qRT–PCR
was detected in the remaining three USPC cell lines (USPC-ARK-1,
USPC-ARK-4 and USPC-ARK-5; range of copies from 4 to 17;
Table 2). The mean copy number in USPC samples overexpressing
TF was 476.3 vs 12.3 in the low USPC TF expressers (Po0.01).
High level of TF was detected in two out of three USPC cell lines
harbouring the amplification of the c-erbB2 gene and in one out of
three USPC cell lines showing low HER2/neu expression (Table 2).
Tissue-factor expression by flow cytometry in primary
USPC cell lines
Surface TF receptor expression was evaluated by fluorescence-
activated cell sorting analysis in all six primary USPC cell lines
using hI-con1 and an anti-human TF control mAb. As negative
controls, several PHA-stimulated PBLs established from healthy
hI-con1 therapy in USPC
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sdonors or the same USPC patients, from whom the tumour cell
lines had been established, were also studied. In agreement with the
RT–PCR results, high reactivity against TF was found using
flow cytometry in USPC-ARK-2, USPC-ARK-3 and USPC-ARK-6
cell lines stained with hI-con1 (Table 2, Figure 2). In contrast,
significantly lower TF surface expression was detected in USPC-
ARK-1, USPC-ARK-4 and USPC-ARK-5 cell lines (Table 2, Figure 2).
Mean fluorescence intensity ranged from 89 to 92 in high USPC TF
expressers vs a mean fluorescence intensity ranged from 25 to 53 in
low USPC TF expressers (Po0.02). Low TF expression was also
observed in the multiple PHA-stimulated PBL lines used as further
controls (i.e., mean fluorescence intensity from 40 to 45; high USPC
TF expressors vs PHA-stimulated PBLs: Po0.01).
Uterine serous papillary adenocarcinoma overexpressing
TF are highly resistant to natural killer (NK) cell activity
but sensitive to IDCC
All the six primary USPC cell lines available were tested for
their sensitivity to NK cell cytotoxicity when challenged with
heterologous PBLs, collected from several healthy donors, in a
standard 5-h
51Cr release assay. Uterine serous papillary adeno-
carcinoma primary cell lines were consistently found to be
resistant to NK cell-mediated cytotoxicity when combined with
PBLs at E:T ratios varying at 25:1–50:1 (range of cytotoxicity
from 0.2–9% with all E:T ratios). Similarly, USPC cell lines
incubated with rituximab (2.5mgml
 1) control antibody showed
no significant cytotoxicity (range from 0.1–8%). We then
investigated the sensitivity of USPC cell lines expressing different
levels of TF to heterologous PBLs in the presence of hI-con1
(30mgml
 1). While negligible levels of cytotoxicity were detected
against PHA-stimulated PBLs (i.e., TF-negative controls, data not
shown), tumour cell lines expressing high levels of TF (i.e., USPC-
ARK-2, USPC-ARK-3 and USPC-ARK-6), regardless of their high
or low HER2/neu expression, were found to be highly sensitive
to hI-con1-induced antibody-dependant cell death (mean±s.d.,
65.6±3.7%; range, 57.5–77.0%; Figure 3; Po0.001). In contrast,
tumour cell lines expressing low levels of TF (i.e., USPC-ARK-1,
USPC-ARK-4 and USPC-ARK-5) were killed at significantly lower
levels when compared with the high TF-expresser USPC cell lines
Figure 1 Representative immunohistochemistry localisation analyses of tissue factor (TF) in uterine serous papillary adenocarcinoma (USPC) specimens.
Upper left panel: normal endometrium, which is negative for TF. Lower left panel: USPC specimen showing cytoplasmic expression of TF. Upper right panel:
USPC specimen showing membrane expression of TF. Lower right panel: USPC specimen showing both cytoplasmic and membrane expressions
of TF. Original magnification:  200.
Table 2 Tissue factor and HER2/neu expression in primary USPC cell lines
HER2/neu IHC HER2/neu FISH Tissue factor RT–PCR
Tissue factor flow cytometry
Sample Cell block Cell block mRNA copy number % Gated MFI
Control — — 1 — —
USPC-ARK-1 3+ 2.5 14.6 86.7 32.7
USPC-ARK-2 3+ 5.2 332.3 100.0 92.2
USPC-ARK-3 3+ 4.7 280.2 100.0 89.8
USPC-ARK-4 0 1.6 4.7 75.6 25.8
USPC-ARK-5 0 1.4 17.6 55.3 53.6
USPC-ARK-6 1+ 0.9 816.4 100.0 92.5
Abbreviations: FISH¼fluorescence in-situ hybridization; IHC¼immunohistochemistry; MFI¼mean fluorescence intensity; RT–PCR¼real-time PCR; USPC¼uterine serous
papillary adenocarcinoma.
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s(Figure 3; Po0.001). Nevertheless, in the latter experiments, low
TF-expresser USPC cell lines incubated with hI-con1 were killed at
significantly higher level when compared with the same tumours
incubated with rituximab control mAb (mean hI-con1 killing
low expresser USPC±s.d.¼14.0±2.0%; range, 10.6–17.6%;
Figure 3; Po0.02), or when compared with PHA-stimulated
PBL control incubated with hI-con1 (mean killing PBLs¼3.0%;
range, 0.6–6%).
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Figure 2 Flow cytometry histograms of primary uterine serous papillary adenocarcinoma (USPC) cell lines showing high (USPC-ARK-2, USPC-ARK-3 and
USPC-ARK-6) and low (USPC-ARK-1, USPC-ARK-4 and USPC-ARK-5) expression of tissue factor. Dashed line represents isotype and solid black
represents human immuno-conjugate molecule.
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Figure 3 Representative cytotoxicity experiments using human immuno-conjugate molecule (hI-con1) against primary uterine serous papillary
adenocarcinoma (USPC) with high vs low tissue factor (TF) expression. Upper panels: high TF USPC cell lines. Lower panels: low TF USPC cell lines.
Negligible cytotoxicity was detected in the absence of hI-con1 or in the presence of rituximab control monoclonal antibody.
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To investigate the effect of low doses of IL-2 in combination
with hI-con1 (30mgml
 1) on IDCC against USPC cell lines, PBLs
from healthy donors were incubated for 5h in the presence of
50–100IUml
 1 of IL-2. As shown in Figure 4, for all primary
USPC showing TF overexpression, (i.e., USPC-ARK-2, USPC-ARK-3
and USPC-ARK-6) IDCC was increased in the presence of
low doses of IL-2. Administration of 50–100IUml
 1 of IL-2 to
the effector PBLs at the start of the assay increased the cytotoxic
activity against USPC cell lines overexpressing TF compared with
the use of hI-con1 alone, (Figure 4; Po 0.01) whereas no
significant increase in cytotoxicity was detected after 5-h IL-2
treatment in the absence of hI-con1 or in the presence of
Rituximab control mAb (Figure 4). These results suggest that
low levels of IL-2 may enhance hI-con1-mediated cell-cytotoxicity
in USPC cell lines in vitro.
DISCUSSION
Tissue factor is involved in pathological angiogenesis and is
abnormally overexpressed in multiple human tumours and in
tumour vascular endothelial cells but not in normal quiescent
vascular endothelial cells (Contrino et al, 1996; Papetti and
Herman, 2002). Although TF, as a cell-surface receptor, is
physiologically expressed on extravascular cells of many organs
and in the adventitial layer of the blood vessel wall, it is
sequestered by coagulation factor VII (fVII), a natural ligand for
TF, at these sites by the tight endothelial-cell layer of the normal
vasculature (Contrino et al, 1996; Papetti and Herman, 2002).
Thus, pathologically expressed TF may provide a target for the
development of novel cancer therapies that are effective not
only against tumour cells but also against tumour blood vessels
(Hu et al, 1999; Hu and Garen, 2000, 2001; Alessi et al, 2004).
In this study, we have evaluated TF expression using IHC in
multiple formalin-fixed, paraffin-embedded USPC samples. In
addition, we have studied TF expression at RNA and protein level
in six primary USPC cell lines and subsequently tested the in vitro
activity of hI-con1, a previously characterized immunoconjugate
molecule developed against TF (Hu et al, 1999; Hu and Garen,
2000, 2001), as a novel therapy against these chemotherapy-
resistant USPC cell lines in vitro (Cross et al, 2010). We observed
TF overexpression on the membrane and/or in the cytoplasm of all
the USPC samples tested using IHC (all 16¼100%) whereas
normal control endometrial cells were found consistently negative
for TF expression. This suggests that TF expression may be a
common and an important event in malignant transformation of
the endometrium, particularly for biologically aggressive type II
endometrial cancer. Consistent with this view, TF was also found
to be highly expressed in three out of six primary USPC cell lines
available for this study, using qRT–PCR and flow cytometry. The
TF expression has been previously reported in endometrial
endometrioid adenocarcinoma cell lines (i.e., the most common
and less aggressive variant of human endometrial cancer; Kato
et al, 2005, 2008). However, to our knowledge, the overexpression
of TF in primary chemotherapy-resistant uterine serous tumours
has not been previously studied. Of interest, in the primary USPC
tested, both HER2/neu-positive and HER2/neu-negative cell lines
were found to overexpress the TF. These data thus suggest that
USPC, regardless of their different sensitivity/resistance to various
chemotherapy agents (Cross et al, 2010) or anti-HER2/neu-
targeted therapies, (i.e., trastuzumab and pertuzumab; El-Sahwi
et al, 2010) may potentially respond to hI-con1 therapy.
Several studies have shown that tumour cell TF has an important
role in tumour metastatic process, possibly by induction of the
coating of the tumour cell with fibrin that would trap the cells in
the microvasculature, thereby aiding metastases (Mueller et al,
1992). More recently, however, a possible direct role for TF
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Figure 4 Effect of low doses of interleukin-2 (IL-2) in combination with
human immuno-conjugate molecule (hI-con1; 30mgml
 1) on antibody-
dependent cell-mediated cytotoxicity against USPC-ARK-2, USPC-ARK-3
and USPC-ARK-6 primary cell lines (effectors to target ratio 25:1).
Peripheral blood lymphocytes (PBLs) from healthy donors were incubated
for 4h in the presence of 100IUml
 1 of IL-2. The hI-con1-mediated
antibody-dependent cell-mediated cytotoxicity was significantly increased in
the presence of low doses of IL-2. No significant increase in cytotoxicity
was detected after 4-h IL-2 treatment in the absence of hI-con1 or in the
presence of the rituximab isotype control monoclonal antibody.
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sin tumour growth has also been suggested by studies showing a
dramatically reduced tumour growth in mice, where a selective
reduction in TF was achieved using small interfering RNA
(Yu et al, 2005). Of great interest, in these studies, is that the
reduction in TF expression did not affect growth of the tumour
cells in vitro, suggesting that TF-mediated enhancement of tumour
growth requires a factor present in vivo that is not present when
cells are grown in vitro (Yu et al, 2005). A potential candidate to
explain these findings is therefore FVIIa, which would form a
TF:FVIIa complex on the surface of tumour cells in vivo leading to
the activation of type-2 proteinase activated receptor-dependent
signalling (Ruf, 2007). These findings combined with our results
suggest that TF overexpression may potentially provide an
additional growth advantage to biologically aggressive USPC
in vivo.
The potential cytotoxic activity of hI-con1 against human
melanoma and prostate tumour cells has previously been shown
by Hu et al (Hu et al, 1999; Hu and Garen, 2000, 2001). In our
study, we extended the results of Hu et al (Hu et al, 1999)
evaluating the cytotoxic potential of hI-con1 against multiple
biologically aggressive, high-grade serous endometrial cancer cell
lines. We found all tested primary tumours showing high TF
expression, regardless of their high or low HER2/neu expression,
to be highly susceptible to IDCC in the presence of effector cells. In
this regard, it is worth noting that although these cell lines were
resistant to NK-cell cytotoxic activity, IDCC resulted in killing of
up to 65% of tumour cells in 5-h
51Cr release assays. Taken
together, these in vitro results strongly suggest that TF may
provide a novel target for USPC and its tumour vasculature, which
should likely result in hI-con1-induced lysis of tumour cells as well
as endothelial cells in vivo.
hI-con1-mediated tumour cell lysis depends on the presence of
effector cells (Hu et al, 1999; Hu and Garen, 2000, 2001), and
CD56-positive lymphocytes have been shown to contribute most to
the effect of IgG1-mediated antibody-dependent cell-mediated
cytotoxicity in vitro as well as in vivo (Ortaldo et al, 1987; Clynes
et al, 2000). Interleukin-2 treatment leads to the activation of NK
cell cytotoxicity and to the expansion of the NK cell population
within the PBL in vivo (Fehniger et al, 2000). Consistent with its
immunostimulatory effect on NK cells, IL-2 has been previously
shown to work synergistically with monoclonal antibodies in vivo
(Caron et al, 1995). Importantly, contrary to the significant toxicity
of high-dose recombinant IL-2 therapy, low-dose IL-2 adminis-
tered subcutaneously or by continuous infusion has been shown to
have high clinical and immunological activity with a low-toxicity
profile (Fehniger et al, 2000). These findings are particularly
interesting because a modulation of the number and function of
NK cells has been associated with tumour progression in both
experimental and animal models, and pre-treatment of the PBLs
with IL-2 can increase the cytotoxicity levels in patients with
suppressed antibody-dependent cell-mediated cytotoxicity to
levels similar to that in normal donors (Ortaldo et al, 1987).
Consistent with this data, our in vitro experiments reveal a
significant increase in hI-con1-induced cytotoxicity after the brief
incubation of PBLs and tumour cells with IL-2 compared with the
cytotoxicity induced by hI-con1 in the absence of IL-2. Inter-
leukin-2 seems to, therefore, enhance the cytotoxic potential of the
effector cells. The administration of low doses of IL-2 might
therefore be a valid therapeutic option to increase IDCC in heavily
pretreated endometrial cancer patients.
Although the in vivo use of hI-con1 in animals harbouring
xenografts of human USPC has not been studied in our current
report, previous studies have shown the safety and efficacy of
using hI-con1 in vivo in mice carrying mouse and human tumours
(Hu et al, 1999; Hu and Garen, 2000, 2001), harbouring human
implants of pathological endometriosis (Krikun et al, 2010), as well
as in eradicating choroidal neovascularization in mouse and pig
models of wet-form macular degeneration (Tezel et al, 2007). Thus,
current studies in multiple animal models suggest that hI-con1 use
is potentially safe in vivo and, therefore, may have great potential
as a neovascular targeting agent, with broad applications for the
immunotherapy of pathological angiogenesis-involved diseases in
humans.
In conclusion, expression of TF in chemotherapy-resistant
USPC makes hI-con1 an attractive agent for immunotherapy of
chemotherapy-resistant endometrial cancer. This holds particu-
larly true for USPC patients, in whom other potentially effective
targeted in vivo therapies (i.e., trastuzumab; Jewell et al, 2006;
Villella et al, 2006; Santin et al, 2008) are not indicated owing to
the lack of expression of its target HER2/neu on USPC cells. In
this study, we have shown significant hI-con1-mediated killing of
high-grade, chemotherapy-resistant USPC, for which treatment
options are very limited. Human immuno-conjugate molecule
(hI-con1) might therefore represent a fascinating new addition to
the treatment of this aggressive disease and, potentially, multiple
other human tumours overexpressing TF. Clinical trials will
ultimately determine the validity of this novel therapeutic
approach.
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